<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466466</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001C2116</org_study_id>
    <nct_id>NCT00466466</nct_id>
  </id_info>
  <brief_title>Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients</brief_title>
  <official_title>A Phase Ib Study Investigating the Combination of RAD001 With Cisplatin and Etoposide in Patients With Extensive-stage Small-cell Lung Cancer Not Previously Treated With Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study aims to establish a tolerable dose level and regimen of RAD001 in combination with
      cisplatin and etoposide (standard-of-care chemotherapy) in patients with extensive stage
      small-cell lung cancer (SCLC) who have not previously been treated with systemic
      chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT) rate will be measured at End-of-Cycle 1</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative dose intensity (RDI) of carboplatin and paclitaxel will be evaluated upon completion of the dose escalation within each regimen</measure>
    <time_frame>within 6 cycles (Day 126)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters derived from the PK profile of treatment drugs when administered alone or in combination will be evaluated during the first 6 cycles</measure>
    <time_frame>During the first 6 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall tumor response</measure>
    <time_frame>Every 6-8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Small-Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Daily dosing RAD001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Weekly dosing RAD001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.</description>
    <arm_group_label>Daily dosing RAD001</arm_group_label>
    <arm_group_label>Weekly dosing RAD001</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with histologically or cytologically confirmed diagnosis of extensive disease
             small-cell lung cancer (ED SCLC)

          -  Age ≥ 18 years

          -  WHO Performance Status Grade ≤ 1 (ie. ability to perform normal daily functions)

          -  Adequate bone marrow, liver and renal function

        Exclusion criteria:

          -  Chronic steroid treatment

          -  Prior treatment with chemotherapy for advanced lung cancer

          -  Prior treatment with mTOR inhibitors

          -  Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers,
             eye conditions, chronic liver or kidney disorders, uncontrolled diabetes, infections
             or other severe medical conditions

          -  Symptomatic or uncontrolled brain metastases

          -  Other cancers within the past 5 years

          -  Pregnant or breastfeeding women

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Faber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center at UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2007</study_first_submitted>
  <study_first_submitted_qc>April 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>November 21, 2011</last_update_submitted>
  <last_update_submitted_qc>November 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Small-Cell Lung Cancer</keyword>
  <keyword>SCLC</keyword>
  <keyword>Advanced Lung Cancer</keyword>
  <keyword>RAD</keyword>
  <keyword>RAD001</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Etoposide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

